At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)
In Brief
A Phase 3 clinical trial evaluating Trabectedin, Doxorubicin, and 1 other intervention for Sarcoma. Completed, enrolled 121 participants across 21 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of trabectedin compared to standard doxorubicin in participants with advanced translocation-related sarcomas (cancer of connective tissue cells) (TRS).
Study Details
Timeline
Interventions
Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.